Lightchain Capital

Recent News

wugen-logo-400
January 26, 2021

Wugen Ramps Up Off-the-Shelf Gene Therapies to Fight Cancer

READ MORE
C4-logo-400
January 19, 2021

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable MonoDAC for Hematologic Malignancies

READ MORE
C4-logo-400
January 07, 2021

C4 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

READ MORE
C4-logo-400
January 06, 2021

C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022

READ MORE
C4-logo-400
December 17, 2020

C4 Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

READ MORE
C4-logo-400
November 25, 2020

C4 Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx

READ MORE
wugen-logo-400
November 19, 2020

Wugen Appoints New Vice President and Head of NK Research as the Company Continues to Expand its Pipeline

READ MORE
C4-logo-400
November 13, 2020

C4 Therapeutics to Present at the Jefferies Virtual London Healthcare Conference

READ MORE
C4-logo-400
November 12, 2020

C4 Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results

READ MORE

Contact Us

Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131

 

LinkedIn

Submit

©2024 LIGHTCHAIN CAPITAL, LLC  All Rights Reserved | Privacy Policy
Website by Tidal Media Group